[TNF inhibitors and myelitis: think about it, even lately]

Marie Stève-Dumont; Mikael Cohen; Christine Lebrun-Frenay; Fanny Rocher

doi:10.2515/therapie/2014031

[TNF inhibitors and myelitis: think about it, even lately]

Therapie. 2014 Sep-Oct;69(5):473-7. doi: 10.2515/therapie/2014031. Epub 2014 Oct 1.

[Article in French]

Authors

Marie Stève-Dumont¹, Mikael Cohen², Christine Lebrun-Frenay², Fanny Rocher¹

Affiliations

¹ Centre régional de pharmacovigilance Nice Alpes-Côte d'Azur, CHU, Nice, France.
² Service de neurologie, CHU, Nice, France.

PMID: 25269140
DOI: 10.2515/therapie/2014031

Abstract

Anti-TNF medications have been widely used for the treatment of auto-immune disease and new drugs are regularly approved. We report here a case of late myelitis after more than 6 years of adalimumab in a 74-year-old woman treated for rheumatoid polyarthritis.

Publication types

Case Reports
English Abstract
Letter

MeSH terms

Adalimumab
Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Arthritis, Rheumatoid / drug therapy
Delayed Diagnosis
Female
Humans
Myelitis / chemically induced*
Myelitis / diagnosis*
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
Adalimumab